, Volume 46, Issue 4, pp 565–567 | Cite as

A case of acute hepatitis A infection in an HIV-positive patient despite complete hepatitis A vaccination

  • Carlos Fritzsche
  • M. Loebermann
  • E. C. Reisinger
Case Report



Vaccination against hepatitis A virus infection is recommended for men who have sex with men and other risk groups. The protection offered by the combined hepatitis A and B vaccine is comparable to that offered by the monovalent hepatitis A vaccine.


A 38-year-old HIV-positive patient presented with right upper abdominal pain, fever and jaundice. Serological work-up and detection of hepatitis A RNA in stool sample revealed an acute hepatitis A infection despite a previous complete vaccination with the combined hepatitis A and B vaccine.


Although the combined hepatitis A and B vaccine is associated with very good seroconversion rates, the effectiveness in HIV-positive patients is not ensured, even in cases with CD4 cell counts of > 500/μl. Therefore, regular post-vaccine testing should be encouraged to assess seroconversion in immunocompromised subjects.


Hepatitis A Vaccine Infection HIV 


Compliance with ethical standards

Conflict of interest

None of the authors has a conflict of interest to declare.


  1. 1.
    Jimenez HR, Hallit RR, DeBari VA, Slim J. Hepatitis A vaccine response in HIV-infected patients: are TWINRIX® and HAVRIX® interchangeable? Vaccine. 2013;31:1328–33.CrossRefPubMedGoogle Scholar
  2. 2.
    Beran J, Van der Meeren O, Leyssen M, D´silva P. Immunity to hepatitis A and B persists for at least 15 years after immunization of adolescents with a combined hepatitis A and B vaccine. Vaccine. 2016;34:2686–91.CrossRefPubMedGoogle Scholar
  3. 3.
    Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis. 2007;5:79–84.CrossRefPubMedGoogle Scholar
  4. 4.
    Mor Z, Lurie Y, Katchman E. A case of hepatitis A vaccination failure in an HIV-positive man who had sex with men in Israel. Int J STD AIDS. 2012;23:529–30.CrossRefPubMedGoogle Scholar
  5. 5.
    Centers for Disease Control and Prevention. Prevention of hepatitis A through active or passive immunization. MMWR. 2006;55:1–23.Google Scholar
  6. 6.
    Beran J. Bivalent inactivated hepatitis A and recombinant hepatitis A vaccine. Expert Rev Vaccines. 2007;6:891–902.CrossRefPubMedGoogle Scholar
  7. 7.
    Elliott JH, Kunze M, Torresi J. Hepatitis A vaccine failure. Lancet. 2002;14:189–93.Google Scholar
  8. 8.
    Loebermann M, Kollaritsch H, Ziegler T, et al. A randomized open-label study of the immunogenicity and reactogenicity of three lots of a combined typhoid fever/hepatitis A vaccine in healthy adults. Clin Ther. 2004;26:1084–91.CrossRefPubMedGoogle Scholar
  9. 9.
    Mena G, Garcia-Basteiro AL, Bayas JM. Hepatitis B and A vaccination in HIV-infected adults: a review. Hum Vaccines Immunother. 2015;11:2582–98.CrossRefGoogle Scholar
  10. 10.
    Mena G, Garcia-Basteiro AL, Llupia A, et al. Factors associated with the immune response to hepatitis A vaccination in HIV-infected patients in the era of highly active antiretroviral therapy. Vaccine. 2013;31:3668–74.CrossRefPubMedGoogle Scholar
  11. 11.
    Overton ET, Nurutdinove D, Sungkanuparph S, Seyfried W, Groger RK, Powderly WG. Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hep. 2007;14:189–93.CrossRefGoogle Scholar
  12. 12.
    Weissman S, Feucht C, Moore BA. Response to hepatitis A vaccine in HIV-positive patients. J Viral Hepatol. 2006;13:81–6.CrossRefGoogle Scholar
  13. 13.
    Bovier PA, Bock J, Ebengo TF, et al. Predicted 30-year protection after vaccination with an aluminium-free virosomal hepatitis A vaccine. J Med Virol. 2010;82:1629–34.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Tropical Medicine and Infectious Diseases, Department of MedicineUniversity of Rostock Medical SchoolRostockGermany

Personalised recommendations